Abstract 1745P
Background
Treatment abandonment (TA) is a major challenge in cancer care leading to poor outcomes and wastage of resources. Reasons for TA are multi-factorial and country specific. Understanding these complexities is the first step toward developing effective strategies for the prevention of TA. Insights and experiences of healthcare workers (HCWs) can provide valuable information about the factors contributing to TA; hence we conducted a qualitative study to understand the issues.
Methods
The participants were purposively selected, experienced HCWs (N=30) treating cancer patients from high-volume cancer centres nationwide. In-depth interviews (semi-structured, open-ended) were conducted by a person trained and experienced in qualitative interviews to understand the perspectives of HCWs on TA among adult cancer patients. We used the grounded theory approach to thematically analyze the data using inductive analysis.
Results
The HCWs (oncologists=17, nurses=6, psycho-oncologists=3, counselors=4) were selected from 9 states of India representing all geographical regions and working in both private (paid services, N= 14) and government (free services, N=16) sectors. The average duration of the interview was 30 minutes, and the reasons for TA perceived by the HCWs were classified under 6 themes: 1) Socio-demographic, 2) Patient-specific, 3) Clinical, 4) Psychological, 5) Health system related, and 6) Economic factors. Catastrophic health expenditure, direct medical and/or non-medical costs, indirect medical costs, poor socio-economic status, lack of specific knowledge about disease and treatment, poor patient-provider communication, accessibility, psychological distress, and toxicities of treatment were the common reasons for TA cited by the HCWs.
Conclusions
The study is one of the first studies reporting on HCWs’ perspective on TA among cancer patients in India. In addition to well-known socio-economic factors, this study identified important themes such as lacunae in communication and psychological issues (e.g., distress) causing TA. The results of this study will help plan quantitative research into the complex issues of TA and interventions to counter the problem.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Ganesan.
Funding
Indian Council of Medical Research-ICMR, New Delhi, India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23